Published in final edited form as:

J Med Chem. 2013 November 14; 56(21): . doi:10.1021/jm401139z.

Tumor-Targeting with Novel Non-Benzoyl 6-Substituted Straight Chain Pyrrolo[2,3-*d*]pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and Inhibition of *de novo* Purine Nucleotide Biosynthesis

Yiqiang Wang^{£,¥,¶}, Christina Cherian^{||,‡,¥}, Steven Orr^{||,‡}, Shermaine Mitchell-Ryan[‡], Zhanjun Hou^{||,‡}, Sudhir Raghavan[£], Larry H. Matherly^{*,||,‡,§,€}, and Aleem Gangjee^{£*,€}

^{£*}Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282

^{||}Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, 110 East Warren Ave, Detroit, MI 48201

[‡]Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201

[§]Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI 48201

Abstract

A new series of 6-substituted straight side chain pyrrolo[2,3-*d*]pyrimidines **3a–d** with varying chain lengths ($n = 5–8$) was designed and synthesized as part of our program to provide targeted antitumor agents with folate receptor (FR) cellular uptake specificity and glycinamide ribonucleotide formyltransferase (GARFTase) inhibition. Carboxylic acids **4a–d** were converted to the acid chlorides and reacted with diazomethane, followed by 48% HBr to generate the α -bromomethylketones **5a–d**. Condensation of 2,4-diamino-6-hydroxypyrimidine **6** with **5a–d** afforded the 6-substituted pyrrolo[2,3-*d*]pyrimidines **7a–d**. Hydrolysis and subsequent coupling with diethyl *L*-glutamate and saponification afforded target compounds **3a–d**. Compounds **3b–d** showed selective cellular uptake via FR α and - β , associated with high affinity binding and inhibition of *de novo* purine nucleotide biosynthesis via GARFTase, resulting in potent inhibition against FR-expressing Chinese hamster cells and human KB tumor cells in culture. Our studies establish, for the first time, that a side chain benzoyl group is not essential for tumor-selective drug uptake by FR α .

INTRODUCTION

Folates are essential for cell growth and tissue regeneration. Membrane transport of extracellular folates is required because mammalian cells cannot synthesize folates *de novo*. Three major folate uptake systems have been reported.^{1–5} (i) The reduced folate carrier

*To whom correspondence should be addressed. Aleem Gangjee, Ph.D., Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282. Phone 412-396-6070; fax 412-396-5593; gangjee@duq.edu. Larry H. Matherly, Ph.D., Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, 110 East Warren Ave, Detroit, MI 48201. Phone 313-578-4280; fax 313-578-4287; matherly@karmanos.org.

¥€These authors contributed equally to this work.

Present Address

Center for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA 02215. 617-667-1839; ywang15@bidmc.harvard.edu

The authors declare no competing financial interest.

Supporting Information. Elemental Analysis. This material is available free of charge via the internet at <http://pubs.acs.org>.

(RFC or SLC19A1) is an anion antiporter that is ubiquitously expressed in tissues and tumors and is the major membrane transport system for folates in mammalian cells at physiologic pH.¹ (ii) Folate receptors (FRs) α and β are glycosyl phosphatidylinositol-anchored proteins that mediate cellular uptake of folates by receptor-mediated endocytosis.^{2,3} High levels of FRs are expressed in a number of malignancies, including ovarian and endometrial cancers (FR α) and in myeloid leukemias (FR β).^{2,3} However, FRs show a more restricted tissue distribution than RFC. In normal tissues where they are expressed, FRs are either inaccessible to circulating folate cofactors (FR α in renal tubules) or are non-functional (FR β in normal hematopoietic cells).^{2,3} (iii) The proton-coupled folate transporter (PCFT; SLC46A1) is a recently discovered proton-folate symporter that functions optimally at acidic pH by coupling the downhill flow of protons to the uphill transport of folates.^{4,5} PCFT is widely expressed in human solid tumors⁴ and in modest levels in most normal tissues, although high levels of PCFT are present in the duodenum and jejunum, as well as in the liver and kidney.⁵

Folate-dependent biosynthetic pathways are important therapeutic targets for cancer chemotherapy.^{6–8} Clinically relevant antifolate drugs for cancer include potent inhibitors of dihydrofolate reductase [methotrexate (MTX), pralatrexate (PDX)], thymidylate synthase [raltitrexed (RTX), pemetrexed (PMX)], and the purine nucleotide biosynthetic enzymes, β -glycinamide ribonucleotide (GAR) formyltransferase (GARFTase) [PMX] and 5-aminoimidazole-4-carboxamide (AICA) ribonucleotide formyltransferase (AICARFTase) [PMX]^{6–8} (Figure 1). Although all these agents are transported by RFC^{1,9}, the expression of RFC in both normal and tumor cells presents a potential obstacle to antitumor selectivity. Further, loss of RFC is frequently associated with antifolate resistance.^{1,8,10} Thus, it is of interest to design tumor-targeted antifolates that are specific substrates for transporters other than RFC with limited expression and/or transport into normal tissues compared with tumors. If these drugs also inhibit targets other than dihydrofolate reductase and thymidylate synthase, this would afford further benefit by circumventing resistance due to increased levels or mutated forms of these enzyme targets. This reasoning was a major impetus to develop novel agents with selective uptake into tumors by FRs or PCFT over RFC, and which specifically target *de novo* purine nucleotide biosynthesis.^{5,6,11–16}

We previously reported a series of 6-substituted pyrrolo[2,3-*d*]pyrimidine phenyl antifolates **2a–d**.^{11,13} (Figure 2) A highly active compound of this series was the 3- carbon bridge (**2a**) which was a targeted agent selectively transported into certain tumor cells by FRs and PCFT but not RFC.^{11,13} Once intracellular, compound **2a** inhibited GARFTase in *de novo* purine nucleotide biosynthesis, resulting in depletion of purine nucleotides.^{11,13} Further, compound **2a** was highly active *in vitro* toward both KB and IGROV1 tumors.¹¹ To further explore the structure-activity relationships (SAR) for GARFTase inhibition and non-RFC targeted transport specificity, we synthesized and tested several series of related analogs with modifications of the aromatic rings and aliphatic linkers.^{5,6,12–16}

Lometrexol (LMTX) is an early generation GARFTase inhibitor¹⁷ that was tested in a phase I clinical trial and was found to be unacceptably toxic.¹⁸ This failure was likely due, at least in part, to its membrane transport into normal cells by RFC. A series of LMTX analogs, **1a–c**, was reported in which the phenyl ring in the bridge was replaced by a methylene bridge of variable length^{19,20} (Figure 2). Interestingly, replacement of the phenyl ring of LMTX by two, three, or four carbon atom chains substantially preserved both binding to GARFTase¹⁹ and polyglutamylation by folylpolyglutamate synthetase (FPGS).²⁰ However, these analogs were not tested for their membrane transport by the major folate transporters or for their capacities to inhibit cell proliferation.

In the present work, we designed an analogous series of 6-substituted pyrrolo[2,3-*d*]pyrimidine analogs to examine the impact of an alkyl-for-benzoyl ring replacement on folate transporter specificity, GARFTase inhibition, and anti-proliferative activities. Straight chain compounds **3a–d** were designed with replacement of the phenyl ring of the lead compound **2a** by methylene bridges of variable lengths ($n = 2–5$) (Figure 2). The precursor acids, **7e–h** (Scheme 1), were also biologically evaluated to determine the importance of the *L*-glutamate moiety to their biological effects. Collectively, our results establish that aliphatic replacement of the benzoyl ring in the 6-substituted pyrrolo[2,3-*d*]pyrimidine series preserves substantial selective FR-directed cellular uptake and GARFTase inhibition, with potent inhibition of tumor cell proliferation, as long as there is sufficient distance between the bicyclic ring system and the terminal *L*-glutamate.

CHEMISTRY

Compounds **3a–d** ($n = 5–8$) were synthesized using an α -bromomethyl ketone condensation with 2,4-diamino-4-oxo-pyrimidine **6** as the key step outlined in Scheme 1. Commercially available carboxylic acids **4a–d** were converted to the acid chlorides and immediately reacted with diazomethane, followed by 48% HBr to give the desired α -bromomethylketones **5a–d**.¹¹ Condensation of 2,4-diamino-6-hydroxypyrimidine **6** with **5a–d** afforded the 6-substituted pyrrolo[2,3-*d*]pyrimidines **7a–d**. Hydrolysis of **7a–d** afforded **7e–h**. Subsequent coupling with diethyl *L*-glutamate using *N*-methyl morpholine and 2,4-dimethoxy-6-chlorotriazine as the activating agents afforded the diesters **8a–d**. Final saponification of the diesters gave the target compounds **3a–d** ($n = 5–8$).

BIOLOGICAL EVALUATION AND DISCUSSION

Non-benzoyl 6-carbon chain pyrrolo[2,3-*d*]pyrimidine antifolates are inhibitors of cell proliferation, correlating with expression of folate receptors

Our goal was to examine the role of the side chain phenyl ring and the terminal *L*-glutamate of the pyrrolo[2,3-*d*]pyrimidine antifolates as determinants of folate transporter selectivity, GARFTase inhibitory activity and anti-proliferative activity, based on prior studies of compounds **2a–d**. We previously showed that the intramolecular distance between the bicyclic scaffold and the *L*-glutamate moiety of the latter series was an important determinant of inhibitory potency toward FR-expressing cell lines,^{10,11,13–15} so this was also examined.

Compounds **3a–d** (Figure 2) and **7e–h** (Scheme 1) were tested in cell proliferation assays with a well-characterized cohort of isogenic Chinese hamster ovary (CHO) sublines previously engineered to individually express the major (anti)folate cellular uptake systems including RFC (PC43-10)²¹, FR α and β (RT16 and D4, respectively)¹¹, or PCFT (R2/PCFT4).^{12,13} Additional testing was performed with KB human nasopharyngeal carcinoma cells which express RFC, FR α , and PCFT.^{11,12} Experiments were performed in standard RPMI 1640/10% dialyzed fetal bovine serum (dFBS) (PC43-10), and in folate-defined media {folate-free RPMI1640/10% dFBS, supplemented with 2 nM (RT16, D4, KB) or 25 nM leucovorin [(6R,S)5-formyl tetrahydrofolate (LCV)] (R2/PCFT4)}. The impact of the drug treatments on cell proliferation was measured after 96 h and results were compared to negative controls including RFC-, FR- and PCFT-null MTXRIIOua^{R2-4} (R2) CHO cells^{11,12,21} [either the parental R2 subline or vector control R2(VC) cells]. For FR-expressing CHO and KB cells, parallel cultures were treated with drugs along with excess folic acid (200 nM) to block drug binding and cellular uptake by FRs. Internalization of exogenous folic acid by FRs would also increase intracellular folate pools. Results were compared with those for the lead 6-substituted pyrrolo[2,3-*d*]pyrimidine benzoyl analogs **2a–d** and are summarized in Table 1.

The data in Table 1 clearly establish that the compounds (**7e–h**) lacking the *L*-glutamate are not inhibitory, regardless of the cell line model tested. Compounds **3a–d** were also inactive up to 1000 nM toward RFC-expressing PC43-10 cells and PCFT-expressing R2/PCFT4 CHO cells. Compounds **3a–d** were inhibitory toward CHO cells engineered to express FR α and FR β , as well as FR α -expressing KB tumor cells. Growth inhibition was abolished in the presence of excess (200 nM) folic acid. The most potent inhibitor was **3c** (7-carbon atom chain), followed by **3d** (8-carbon chain) and **3b** (6-carbon chain). The 5-carbon chain analog, **3a**, was a much poorer inhibitor of cell proliferation. Growth inhibitions, as reflected in the IC₅₀ values, were similar with FR α -expressing sublines (KB, RT16) for compounds **2a**, **2b**, **3c** and **3d**. Whereas sensitivities of FR α -expressing RT16 cells were similar to those for FR β -expressing D4 cells for compounds **2a** and **2b**, D4 cells were distinctly more sensitive to the non-benzoyl compounds **3b–3d**. The FR specificity for the active analogs of this series contrasts with results with classic antifolates including MTX, RTX, PMX, PDX, and LMTX, for which anti-proliferative activities for RFC- and PCFT-expressing cells exceeded those for FR-expressing cells (Table 1).

Binding of non-benzoyl pyrrolo[2,3-*d*]pyrimidine antifolates to FR α and β

Compounds **3a–d** are all inhibitors of proliferation for cell lines that express FR α (RT16, KB) and FR β (D4) (Table 1). The inhibitory effects of these active compounds were blocked by excess folic acid, consistent with their surface binding and internalization by FRs.

Surface FR binding of cytotoxic folate analogs is an essential step for drug internalization by this mechanism and for inhibition of intracellular enzyme targets.^{11,12,14–16} To establish a SAR for FR α and β binding of this series, in particular the impact of alkyl chain length (5–8 carbons) for the 6-substituted analogs and of the terminal *L*-glutamate on FR binding, we performed competitive binding assays with compounds **3a–d** and **7e–h** at pH 7.4. In these experiments, unlabeled pyrrolo[2,3-*d*]pyrimidine compounds were tested for their abilities to compete for surface FR binding with [³H]folic acid. FR binding of unknown ligands was compared to those for positive (compounds **2a** and **2b**, also folic acid) and negative (MTX) controls, with documented FR-binding characteristics. The CHO sublines expressing FR α (RT16) or FR β (D4) were initially rinsed with acid-buffered saline to release FR-bound folates, followed by incubation with [³H]folic acid (at pH 7.4), in the presence of unlabeled (anti)folate competitors over a range of concentrations.^{11,12,14–16} After further washing the cells (pH 7.4), FR-bound [³H]folic acid was quantitated and normalized to cell protein and results calculated as pmol [³H]folic acid bound to FRs per mg cell protein. Relative affinities were expressed as inverse molar ratios of (anti)folates required to decrease bound [³H]folic acid by 50% normalized to the affinity for unlabeled folic acid in each experiment (assigned a value of 1.0).^{11,12,14–16} The results are expressed as mean values $\pm$ standard errors and are presented in Figure 3.

With the 6-substituted analogs that included terminal *L*-glutamates (**3a–d**), FR binding increased with increasing substituent chain length (**3d** > **3c** > **3b** > **3a**) for both FR α and β , with compound **3d** exhibiting relative binding affinities approximating those for compounds **2a** and **2b**, and slightly less than for folic acid (Figure 3). The lack of a terminal *L*-glutamate (compounds **7e–h**) had a deleterious effect on FR binding, consistent with the results for the cell proliferation experiments (Table 1). For FR α (but not FR β), compound **7h** with the 8-carbon chain showed detectable binding. Interestingly, binding of the active linear analogs (compounds **3b**, **3c**, and **3d**) was consistently reduced for FR β compared to FR α , in spite of their increased inhibitory effects toward FR β -expressing D4 cells over FR α -expressing RT16 cells (Table 1).

These results demonstrate that the presence of a phenyl side chain ring system for the 6-substituted pyrrolo[2,3-*d*]pyrimidine analogs is not obligatory for binding to FR α or - β . Further, whereas FR binding is clearly critical to cellular uptake of cytotoxic folate analogs, this parameter shows at best an inexact correlation with anti-proliferative activities of the non-benzoyl pyrrolo[2,3-*d*]pyrimidine series of analogs. Nonetheless, FR binding for both FR α and β was greatest for the compounds (**3c** and **3d**) with the most potent anti-proliferative effects.

Determination that GARFTase is the major cellular target for compounds **3b**, **3c** and **3d**

Previous reports of non-benzoyl analogs of LMTX, **1a–c**, in which the phenyl ring was replaced by 2–4 methylene groups (Figure 2) established that the aromatic B ring is not essential for binding to the GARFTase active site, as these novel antifolate compounds were potently inhibitory toward purified murine GARFTase.¹⁹ Further, compounds **1a–c** were all excellent substrates for polyglutamylation by murine FPGS.²⁰ By analogy to compounds **1a–c** and the parent 6-substituted pyrrolo[2,3-*d*]pyrimidines **2a** and **2b**, we hypothesized that the non-benzoyl analogs **3b–d** were also GARFTase inhibitors. To establish the targeted pathway for compounds **3b–d** (i.e., *de novo* thymidylate versus *de novo* purine nucleotide biosynthesis), exogenous thymidine and adenosine were tested for their capacities to reverse their growth inhibitory effects toward KB cells (Figure 4).^{11–17} AICA, a precursor of the AICARFTase substrate was added to circumvent the step catalyzed by GARFTase so as distinguish inhibition of GARFTase from AICARFTase.^{11–17}

For non-benzoyl pyrrolo[2,3-*d*]pyrimidine analogs **3b–d**, thymidine (10 μ M) had no impact on the extent of inhibition of cellular proliferation, indicating that thymidylate biosynthesis (i.e., thymidylate synthase) was not being targeted. Conversely, both adenosine (60 μ M) and AICA (320 μ M) completely reversed the inhibitory effects of this series, establishing that *de novo* purine nucleotide biosynthesis in general, and GARFTase in particular were the likely intracellular targets (Figure 4). Essentially identical results were previously published for compounds **2a** and **2b**.¹¹ In addition, in experiments with recombinant DHFR and TS, compounds **3b–3d** were not inhibitory (data not shown).

We used an *in situ* activity assay to *directly* measure cellular GARFTase activity in KB cells treated with the novel antifolates.^{11–17} Cells were incubated with [¹⁴C]glycine as a radiotracer for 15 h in the presence of compounds **3b–d** under conditions and at concentrations approximating those used in the cell proliferation experiments (Table 1). In this metabolic assay, [¹⁴C]glycine is incorporated into the GARFTase substrate [¹⁴C] GAR and subsequently into [¹⁴C]formyl GAR (by GARFTase) which accumulates in the presence of azaserine. Following protein precipitation with trichloroacetic acid, the acid-soluble metabolites are extracted and fractionated by ion-exchange chromatography, permitting quantitation of [¹⁴C]formyl GAR normalized to cellular protein.

The results show that in KB cells, compounds **3b–d** were all potent GARFTase inhibitors at extracellular drug concentrations approximating those required to inhibit cell proliferation (Figure 5). Calculated IC₅₀ values for GARFTase inhibition varied within a 3-fold range from 2.89 for compound **3b** to 9.62 nM for compound **3d**. By comparison, the IC₅₀s for the 3- and 4-carbon benzoyl analogs **2a** and **2b** were 18 and 6.8 nM, respectively.¹¹

These results unambiguously demonstrate that the absence of a side chain benzoyl ring system in the 6-substituted pyrrolo[2,3-*d*]pyrimidine series is not required to potently inhibit intracellular GARFTase, analogous to results for the non-benzoyl analogs of LMTX **1a–c** (Figure 1).

Molecular modeling: docking studies of compound **3c** with human GARFTase

Figure 6 shows the docked pose of **3c** ($n=7$) in the human GARFTase (PDB ID: 1NJS)²² active site. The cofactor binding pocket of GARFTase is located at the interface between the N-terminal mononucleotide binding domain and the C-terminal half of the structure. The binding site for the folate cofactor moiety consists of three parts: the pteridine binding cleft, the benzoylglutamate region, and the formyl transfer region.²² The docked pose shows the pyrrolo[2,3-*d*]pyrimidine scaffold of **3c** to be buried deep in the active site and occupies the same location as the diaminopyrimidone ring in the native crystal structure ligand 10-trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-CF₃CO-DDACTHF). This orientation of the scaffold permits the 2-amino moiety of **3c** to form hydrogen bonds to Glu141 and the backbone of Leu92. The N1 nitrogen interacts with the backbone of Leu92 to form a hydrogen bond. The 4-oxo moiety forms a hydrogen bond with Asp144 and forms water-mediated hydrogen bonds with Asp142 and Ala140. The molecule is oriented in a manner that aids the N7-nitrogen to form a hydrogen bond with Arg90. As is shown with 10-CF₃CO-DDACTHF (Figure 6), several hydrophobic residues flank the pocket which holds the pyrrolo[2,3-*d*]pyrimidine scaffold. The hydrophobic pocket consists of Leu85, Ile91, Leu92, Val97 (not shown), and the folate binding loop residues 141–146. The amide NH of the *L*-glutamate forms a hydrogen bond with Met89. The 7-carbon side chain of **3c** shifts the glutamate side chain away from the corresponding glutamate side chain of 10-CF₃CO-DDACTHF. The carbonyl group of the glutamate side chain of **3c** interacts with Arg64, which is not seen with the corresponding carbonyl group of the side chain of 10-CF₃CO-DDACTHF. The γ -carboxylic acid of **3c** interacts with Arg64. The α -carboxylic acid of the glutamate side chain of **3c** interacts with Arg90. Thus, the interaction pattern of the α - and γ -carboxylic acid moieties of **3c** are reversed compared to the corresponding α - and γ -carboxylic acids of 10-CF₃CO-DDACTHF and could represent an alternate conformation of the side chain. These interactions could easily permit binding and potent inhibition of **3c** against GARFTase, as demonstrated by the results of our *in situ* GARFTase assays (Figure 5).

Molecular modeling: docking studies of compound **3c** with human FR α

The X-ray crystal structure of human FR α with folic acid was recently published.²³ Accordingly, we determined the docked structure of **3c** (a prototype of the nonbenzoyl series of 6-substituted pyrrolo-[2,3-*d*]pyrimidine analogs) with FR α .

Figure 7 shows the docked pose of compound **3c** in the human FR α (PDB ID: 4LRH)²³ binding site. The long and open folate-binding pocket of FR α contains a predominantly negatively charged pocket where the pterate group of folic acid binds, and a positively charged entrance of the binding pocket which is occupied by the glutamate moiety of folic acid. In its docked pose, the pyrrolo[2,3-*d*]pyrimidine scaffold of **3c** binds similar to the pterin scaffold of folic acid. The 2-NH₂ moiety of **3c** interacts with the side chain carboxylic acid of Asp81. Additional hydrogen bonds are formed between N3 and the side chain hydroxyl of Ser174 and between the 4-oxo group and the side chain NH of Arg103 and His135. The pyrrolo[2,3-*d*]pyrimidine scaffold is sandwiched between the side chains of Tyr60 and Tyr171, similar to the pteridine ring seen in the bound conformation of folic acid. The pyrrole NH of **3c** does not interact with the binding pocket. The flexible C6-substituted chain in **3c** enables the glutamate moiety to be oriented similarly to the corresponding groups in folic acid. The α -carboxylic acid of **3c** can form hydrogen bonds with the backbone NH of Gly137 and Trp138 while the γ -carboxylic acid interacts with the backbone NH of Lys136 and the side chain NH of Trp102. The hydrophobic C6-linker of **3c** can interact in the linker region with surrounding hydrophobic amino acids such as Tyr60, Phe62, Trp102, Trp134 and His135. The docking score of **3c** with FR α was -46.4850.

Conclusions

There is growing interest in tumor targeting of cytotoxic folate-based therapeutics via their selective cellular uptake by FRs or PCFT over RFC.^{5,6,11–16} Specific uptake by FRs or PCFT but not RFC would afford these analogs selectivity for tumor cells expressing FR α and $-\beta$ and/or PCFT and significant advantages over classical antifolates such as RTX or PMX that are transported by all systems.^{1,5}

In previous studies, we began establishing a SAR for FR and PCFT binding and cellular uptake vis á vis RFC, and of GARFTase inhibition in *de novo* purine nucleotide biosynthesis.^{5,6,11–16} Hence, (i) the 6-substituted pyrrolo[2,3-*d*]pyrimidine ring system, (ii) a thienoyl-for-benzoyl B ring replacement, and (iii) optimal spacing between the pyrrolo[2,3-*d*]pyrimidine system and the terminal *L*-glutamate all favored FR and PCFT cellular uptake and GARFTase inhibition, resulting in potent anti-proliferative activity.^{5,6,11–16}

In this report, we continued our systematic study of structural determinants of cellular uptake by RFC, PCFT, and FRs α and β . A novel series of classical 6-substituted straight chain pyrrolo[2,3-*d*]pyrimidine antifolates **3a–d** was designed and synthesized as analogs of **2a** with replacement of the phenyl ring by a linear carbon chain of variable lengths ($n = 2–5$) with or without the terminal *L*-glutamate. Our results demonstrate, for the first time, that the presence of the phenyl side chain ring is not essential for binding and cellular uptake by FRs. There is an absolute requirement for a terminal *L*-glutamate and there is an optimal distance for the alkyl linker separating the pyrrolo[2,3-*d*]pyrimidine ring system and the *L*-glutamate moiety. The lack of a requirement of the phenyl side chain for FR-mediated cellular uptake is consistent with structural data for FR α ²³ and our docking results with compound **3c** and FR α which show that this region of the molecule interacts with FR α only via hydrophobic interactions.

There were modest differences in surface binding to FR α and $-\beta$ at neutral pH between the active analogs, **3b–d**, with binding to FR α exceeding that for FR $-\beta$. However, this did not translate into corresponding differences in *in vitro* drug efficacies toward isogenic CHO cell line models expressing one or the other transport system. Rather, inhibition of proliferation of FR β -expressing CHO cells exceeded that for FR α -expressing CHO cells. This apparent discrepancy may reflect differences in relative affinities of bound substrates at the acidic pH conditions of the endosome for FR α and β . FR β but not FR α was found to show (by isothermal titration calorimetry) a pH-dependent decrease in binding affinities for number of classic antifolates (MTX, aminopterin, PMX) at acidic versus neutral pH.²⁴ By analogy, for the linear 6-substituted pyrrolo[2,3-*d*]pyrimidine analogs, in spite of their slightly decreased binding affinities for FR β at pH 7.4, bound drugs may be more effectively released in the endosome than drugs bound to FR α .

For both FR α and $-\beta$, the most active compounds of the present series, compounds **3c** and **3d**, bound with the highest affinities and inhibited proliferation of FR-expressing CHO and KB tumor cells with nanomolar potencies approaching those of compounds **2a** and **2b**, among the most potent 6-substituted pyrrolo[2,3-*d*]pyrimidine analogs previously reported by us^{5,11}, albeit without any evidence of PCFT transport. Likewise, there was no indication of RFC membrane transport, as an engineered CHO cell line expressing ample human RFC and established *in vitro* cytotoxicities to RFC antifolate substrates was completely unaffected by the most potent non-benzoyl analogs.

Our results establish that although the phenyl side chain is not essential for FR binding and cellular uptake, it appears to be absolutely necessary for PCFT transport. Inhibition of cell proliferation was attributable to potent inhibition of GARFTase in *de novo* purine nucleotide bioynthesis at concentrations approximating those which inhibited cell proliferation. Thus,

our results are entirely consistent with previous reports that the absence of a side chain phenyl ring in a series of non-benzoyl analogs of LMTX analogs preserved substantial catalytic activity for FPGS and inhibition of isolated GARFTase.^{19,20} The structural simplicity and extraordinary antitumor activities of the 6-substituted straight chain compounds described herein provide an excellent starting point for future rational design efforts to further optimize selective cellular uptake by FRs and GARFTase inhibition as an important step toward discovering additional potent targeted antitumor agents.

EXPERIMENTAL SECTION

All evaporations were carried out *in vacuo* with a rotary evaporator. Analytical samples were dried *in vacuo* (0.2 mmHg) in a CHEM-DRY drying apparatus over P₂O₅ at 80 °C. Melting points were determined on a MEL-TEMP II melting point apparatus with a FLUKE 51 K/J electronic thermometer and are uncorrected. Nuclear magnetic resonance spectra for proton (¹H NMR) were recorded on either a Bruker WH-400 (400 MHz) spectrometer or a Bruker WH-500 (500 MHz) spectrometer. The chemical shift values are expressed in ppm (parts per million) relative to tetramethylsilane as an internal standard: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad singlet. Mass spectra were recorded on a VG-7070 double-focusing mass spectrometer or in a LKB-9000 instrument in the electron ionization (EI) mode. Chemical names follow IUPAC nomenclature. Thin-layer chromatography (TLC) was performed on Whatman Sil G/UV254 silica gel plates with a fluorescent indicator, and the spots were visualized under 254 and 365 nm illumination. All analytical samples were homogeneous on TLC in three different solvent systems. Proportions of solvents used for TLC are by volume. Column chromatography was performed on a 230–400 mesh silica gel (Fisher, Somerville, NJ) column. Elemental analyses were performed by Atlantic Microlab, Inc., Norcross, GA. Element compositions are within 0.4% of the calculated values. Fractional moles of water frequently found in the analytical sample of antifolates could not be prevented in spite of 24–48 h of drying *in vacuo* and were confirmed where possible by the presence in the ¹H NMR spectra. All solvents and chemicals were purchased from Aldrich Chemical Co. or Fisher Scientific and were used as received. For all the compounds submitted for biological evaluation, elemental analysis (C, H, N) was performed to confirm >95% purity.

Ethyl 8-bromo-7-oxooctanoate (5a)

To a solution of 7-methoxy-7-oxoheptanoic acid (**4a**) (0.32 g, 1.5 mmol) in a 50 mL flask was added oxalyl chloride (1.5 mL) and anhydrous CH₂Cl₂ (10 mL). The resulting solution was refluxed for 1 h and then cooled to room temperature. After evaporation of solvent under reduced pressure, the residue was dissolved in ethyl ether (20 mL). The resulting solution was added dropwise to an ice-cold ether solution of diazomethane (generated *in situ* from 1.4 g *N*-nitroso-*N*-methylurea) over 10 min. To this solution was added 48% HBr (1.5 mL). The resulting mixture was refluxed for 1.5 h. After the mixture was cooled to room temperature, the organic layer was separated and the aqueous layer was extracted with ethyl ether (20 mL x 3). The combined organic layers were washed with two portions of 10% Na₂CO₃ solution and dried over Na₂SO₄. The solvent was evaporated to afford 0.38 g **5a**: yield 79% as white crystals, mp 68–69 °C, *R*_f = 0.50 (Hexane/EtOAc, 5:1). ¹H NMR (CDCl₃) δ 1.24–1.27 (t, 3 H, CH₃, *J* = 7.5 Hz), 1.32–1.37 (m, 2 H, CH₂), 1.62–1.65 (m, 4 H, 2 CH₂), 2.28–2.31 (t, 2 H, CH₂, *J* = 7.5 Hz), 2.65–2.69 (m, 2 H, CH₂), 3.87 (s, 2H, CH₂Br), 4.10–4.14 (q, 2 H, CH₂, *J* = 7.5 Hz).

Methyl 9-bromo-8-oxononanoate (5b)

Compound **5b** was synthesized as described for **5a**: yield 83% as light yellow crystals, mp 70–71 °C, *R*_f = 0.51 (Hexane/EtOAc, 5:1). ¹H NMR (CDCl₃) δ 1.32–1.33 (m, 4 H, 2 CH₂),

1.60–1.63 (m, 4 H, 2 CH₂), 2.28–2.31 (t, 2 H, CH₂, $J = 7.5$ Hz), 2.63–2.66 (t, 2 H, CH₂, $J = 7.5$ Hz), 3.66 (s, 3H, CH₃), 3.87 (s, 2H, CH₂Br).

Methyl 10-bromo-9-oxodecanoate (5c)

Compound **5c** was synthesized as described for **5a**: yield 78% as yellow crystals, mp 123–124 °C, $R_f = 0.51$ (Hexane/EtOAc, 5:1). ¹H NMR (CDCl₃) δ 1.31–1.33 (m, 6 H, 3 CH₂), 1.60–1.62 (m, 4 H, 2 CH₂), 2.28–2.31 (t, 2 H, CH₂, $J = 7.5$ Hz), 2.63–2.66 (t, 2 H, CH₂, $J = 7.5$ Hz), 3.66 (s, 3H, CH₃), 3.87 (s, 2H, CH₂Br).

Methyl 11-bromo-10-oxoundecanoate (5d)

Compound **5d** was synthesized as described for **5a**: yield 72% as yellow crystals, mp 92–93 °C, $R_f = 0.52$ (Hexane/EtOAc, 3:1). ¹H NMR (CDCl₃) δ 1.31–1.33 (m, 8 H, 4 CH₂), 1.59–1.62 (m, 4 H, 2 CH₂), 2.28–2.31 (t, 2 H, CH₂, $J = 7.5$ Hz), 2.62–2.65 (t, 2 H, CH₂, $J = 7.5$ Hz), 3.66 (s, 3H, CH₃), 3.87 (s, 2H, CH₂Br).

Ethyl 6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)hexanoate (7a)

To a suspension of 2,4-diamino-6-hydroxypyrimidine **6** (1.26 g, 10.0 mmol) in anhydrous DMF (40 mL) was added **5a** (2.64 g, 10.0 mmol). The resulting mixture was stirred under N₂ at room temperature for 3 days. TLC showed the disappearance of starting materials and the formation of one major spot. After evaporation of solvent, CH₃OH (20 mL) was added followed by silica gel (5 g). Evaporation of the solvent afforded a plug, which was loaded onto a silica gel column (3.5 cm x 15 cm) and eluted initially with CHCl₃ followed by 10% MeOH in CHCl₃ and then 15% MeOH in CHCl₃. Fractions showing $R_f = 0.39$ were pooled and evaporated to afford 1.20 g **7a**: yield 41% as a yellow solid, mp 189–190 °C, $R_f = 0.39$ (CHCl₃/MeOH, 5:1). ¹H NMR (DMSO-*d*₆) δ 1.15–1.17 (t, 3 H, CH₃, $J = 7.5$ Hz), 1.26–1.31 (m, 2 H, CH₂), 1.52–1.57 (m, 4 H, 2 CH₂), 2.25–2.28 (t, 2 H, CH₂, $J = 7.5$ Hz), 2.44–2.47 (t, 2 H, CH₂, $J = 7.5$ Hz), 4.01–4.06 (m, 2 H, OCH₂), 5.84 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH₂), 10.10 (s, 1 H, 3-NH), 10.77 (s, 1H, 7-NH).

Methyl 7-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)heptanoate (7b)

Compound **7b** was synthesized as described for **7a**: yield 39% as a yellow solid, mp 178–179 °C, $R_f = 0.39$ (CHCl₃/MeOH, 5:1). ¹H NMR (DMSO-*d*₆) δ 1.24–1.29 (m, 4 H, 2 CH₂), 1.49–1.56 (m, 4 H, 2 CH₂), 2.27–2.30 (t, 2 H, CH₂, $J = 7.5$ Hz), 2.44–2.47 (m, 2 H, CH₂), 3.57 (s, 3 H, OCH₃), 5.83 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH₂), 10.11 (s, 1 H, 3-NH), 10.77 (s, 1H, 7-NH).

Methyl 8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)octanoate (7c)

Compound **7c** was synthesized as described for **7a**: yield 43% as a yellow solid, mp 162–163 °C, $R_f = 0.41$ (CHCl₃/MeOH, 5:1). ¹H NMR (DMSO-*d*₆) δ 1.21–1.30 (m, 6 H, 3 CH₂), 1.49–1.56 (m, 4 H, 2 CH₂), 2.27–2.29 (t, 2 H, CH₂, $J = 7.5$ Hz), 2.43–2.47 (t, 2 H, CH₂, $J = 7.5$ Hz), 3.57 (s, 3 H, OCH₃), 5.84 (s, 1 H, CH), 6.00 (s, 2 H, 2-NH₂), 10.16 (s, 1 H, 3-NH), 10.79 (s, 1H, 7-NH).

Methyl 9-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)nonanoate (7d)

Compound **7d** was synthesized as described for **7a**: yield 42% as a yellow solid, mp 165–166 °C, $R_f = 0.41$ (CHCl₃/MeOH, 5:1). ¹H NMR (DMSO-*d*₆) δ 1.21–1.30 (m, 8 H, 4 CH₂), 1.49–1.56 (m, 4 H, 2 CH₂), 2.26–2.29 (t, 2 H, CH₂, $J = 7.5$ Hz), 2.44–2.47 (t, 2 H, CH₂, $J = 7.5$ Hz), 3.57 (s, 3 H, OCH₃), 5.85 (s, 1 H, CH), 6.03 (s, 2 H, 2-NH₂), 10.20 (s, 1 H, 3-NH), 10.81 (s, 1H, 7-NH).

6-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)hexanoic acid (7e)

To a solution of the ester **7a** (100 mg, 0.26 mmol) was added 1N NaOH (5 mL), and the mixture was stirred under N₂ at room temperature for 1 h. TLC showed the disappearance of the starting material and formation of one major spot at the origin (CHCl₃/MeOH, 5:1). The resulting solution was cooled in an ice bath, and the pH was adjusted to 3–4 with dropwise addition of 1N HCl or acetic acid. The resulting suspension was frozen in a dry ice/acetone bath, thawed in a refrigerator to 4–5 °C, and filtered. The residue was washed with a small amount of cold water, dichloromethane and ethyl acetate and dried *in vacuo* using P₂O₅ to afford 81 mg **7e**: yield 93% as a yellow powder, mp 188–189 °C decomposed, *R*_f = 0.06 (CHCl₃/MeOH, 5:1). ¹H NMR (DMSO-*d*₆) δ 1.20–1.30 (m, 2 H, CH₂), 1.47–1.56 (m, 4 H, 2 CH₂), 2.17–2.20 (t, 2 H, CH₂, *J* = 7.5 Hz), 2.43–2.47 (t, 2 H, CH₂, *J* = 7.5 Hz), 5.83 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH₂), 10.11 (s, 1 H, 3-NH), 10.77 (s, 1H, 7-NH), 11.95 (s, 1H, COOH). Anal. (C₁₂H₁₆N₄O₃ · 0.2 CH₃COOC₂H₅ · 0.2 CH₃COOH) C, H, N.

7-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)heptanoic acid (7f)

Compound **7f** was synthesized as described for **7e**: yield 91% as a brown powder, mp 200–201 °C decomposed, *R*_f = 0.08 (CHCl₃/MeOH, 5:1). ¹H NMR (DMSO-*d*₆) δ 1.20–1.30 (m, 4 H, 2 CH₂), 1.47–1.56 (m, 4 H, 2 CH₂), 2.17–2.20 (t, 2 H, CH₂, *J* = 7.5 Hz), 2.44–2.47 (t, 2 H, CH₂, *J* = 7.5 Hz), 5.83 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH₂), 10.11 (s, 1 H, 3-NH), 10.77 (s, 1H, 7-NH), 11.95 (s, 1H, COOH). Anal. (C₁₃H₁₈N₄O₃ · 0.6 CH₃OH) C, H, N.

8-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)octanoic acid (7g)

Compound **7g** was synthesized as described for **7e**: yield 89% as a brown powder, mp 211–212 °C decomposed, *R*_f = 0.06 (CHCl₃/MeOH, 5:1). ¹H NMR (DMSO-*d*₆) δ 1.20–1.30 (m, 6 H, 3 CH₂), 1.47–1.56 (m, 4 H, 2 CH₂), 2.17–2.20 (t, 2 H, CH₂, *J* = 7.5 Hz), 2.43–2.47 (t, 2 H, CH₂, *J* = 7.5 Hz), 5.83 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH₂), 10.10 (s, 1 H, 3-NH), 10.76 (s, 1H, 7-NH), 11.94 (s, 1H, COOH). Anal. (C₁₄H₂₀N₄O₃ · 0.4 H₂O) C, H, N.

9-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)nonanoic acid (7h)

Compound **7h** was synthesized as described for **7e**: yield 95% as a brown powder, mp 186 °C decomposed, *R*_f = 0.09 (CHCl₃/MeOH, 5:1). ¹H NMR (DMSO-*d*₆) δ 1.20–1.30 (m, 8 H, 4 CH₂), 1.45–1.56 (m, 4 H, 2 CH₂), 2.17–2.20 (t, 2 H, CH₂, *J* = 7.5 Hz), 2.44–2.47 (t, 2 H, CH₂, *J* = 7.5 Hz), 5.83 (s, 1 H, CH), 5.97 (s, 2 H, 2-NH₂), 10.13 (s, 1 H, 3-NH), 10.77 (s, 1H, 7-NH), 11.95 (s, 1H, COOH). Anal. (C₁₅H₂₂N₄O₃ · 0.46 CH₂Cl₂) C, H, N.

(S)-Diethyl 2-(6-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)hexanamido)pentanedioate (8a)

To a suspension of **7e** (81 mg, 0.34 mmol) in anhydrous DMF (5 mL) was added 6-chloro-2,4-dimethoxy-1,3,5-triazine (72 mg, 0.42 mmol) and *N*-methylmorpholine (43 mg, 0.42 mmol). After the mixture was stirred at r.t. for 2 h, *N*-methylmorpholine (43 mg, 0.42 mmol) and diethyl *L*-glutamate hydrochloride (120 mg, 0.51 mmol) were added all at once. The mixture was stirred at r.t. for 4 h. TLC showed the formation of one major spot at *R*_f = 0.62 (CHCl₃/MeOH, 5:1). The reaction mixture was evaporated to dryness under reduced pressure. The residue was dissolved in a minimum amount of CHCl₃/MeOH, 5:1, and chromatographed on a silica gel column (2 cm x 15 cm) with 4% MeOH in CHCl₃ as the eluent. Fractions that showed the desired single spot at *R*_f = 0.62 were pooled and evaporated to dryness to afford **8a** 102 mg: yield 67% as a yellow syrup, *R*_f = 0.62 (CHCl₃/MeOH, 5:1). ¹H NMR (DMSO-*d*₆) δ 1.15–1.18 (t, 6 H, 2 CH₃, *J* = 7.0 Hz), 1.23–1.29 (m, 2 H, CH₂), 1.48–1.58 (m, 4 H, 2 CH₂), 1.76–1.82 (m, 1 H, CH), 1.92–1.98 (m, 1 H, CH), 2.09–2.12 (t, 2 H, CH₂, *J* = 7.0 Hz), 2.33–2.37 (m, 2 H, CH₂), 2.44–2.47 (m, 2 H, CH₂),

4.02–4.07 (m, 4 H, 2 CH₂), 4.19–4.24 (m, 1 H, CH), 5.84 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH₂), 8.16 (d, 1 H, CONH, *J* = 3.8 Hz), 10.10 (s, 1 H, 3-NH), 10.76 (s, 1H, 7-NH).

(S)-Diethyl 2-(7-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)heptanamido)pentanedioate (8b)

Compound **8b** was synthesized as described for **8a**: yield 70% as a yellow syrup, *R_f* = 0.62 (CHCl₃/MeOH, 5:1). ¹H NMR (DMSO-*d*₆) δ 1.15–1.18 (m, 6 H, 2 CH₃), 1.23–1.30 (m, 4 H, 2 CH₂), 1.48–1.58 (m, 4 H, 2 CH₂), 1.76–1.82 (m, 1 H, CH), 1.92–1.99 (m, 1 H, CH), 2.09–2.12 (t, 2 H, CH₂, *J* = 7.0 Hz), 2.33–2.37 (m, 2 H, CH₂), 2.44–2.47 (m, 2 H, CH₂), 4.02–4.08 (m, 4 H, 2 CH₂), 4.20–4.24 (m, 1 H, CH), 5.83 (s, 1 H, CH), 5.93 (s, 2 H, 2-NH₂), 8.15 (d, 1 H, CONH, *J* = 3.8 Hz), 10.10 (s, 1 H, 3-NH), 10.77 (s, 1H, 7-NH).

(S)-Diethyl 2-(8-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)octanamido)pentanedioate (8c)

Compound **8c** was synthesized as described for **8a**: yield 68% as a yellow syrup, *R_f* = 0.64 (CHCl₃/MeOH, 5:1). ¹H NMR (DMSO-*d*₆) δ 1.16–1.19 (t, 6 H, 2 CH₃, *J* = 7.0 Hz), 1.22–1.32 (m, 6 H, 3 CH₂), 1.47–1.57 (m, 4 H, 2 CH₂), 1.76–1.82 (m, 1 H, CH), 1.92–1.99 (m, 1 H, CH), 2.09–2.12 (t, 2 H, CH₂, *J* = 7.0 Hz), 2.34–2.37 (m, 2 H, CH₂), 2.45–2.48 (m, 2 H, CH₂), 4.02–4.08 (m, 4 H, 2 CH₂), 4.20–4.24 (m, 1 H, CH), 5.84 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH₂), 8.15 (d, 1 H, CONH, *J* = 3.8 Hz), 10.10 (s, 1 H, 3-NH), 10.76 (s, 1H, 7-NH).

(S)-Diethyl 2-(9-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)nonanamido)pentanedioate (8d)

Compound **8d** was synthesized as described for **8a**: yield 66% as a yellow syrup, *R_f* = 0.64 (CHCl₃/MeOH, 5:1). ¹H NMR (DMSO-*d*₆) δ 1.15–1.18 (t, 6 H, 2 CH₃, *J* = 7.0 Hz), 1.22–1.32 (m, 8 H, 4 CH₂), 1.47–1.57 (m, 4 H, 2 CH₂), 1.76–1.82 (m, 1 H, CH), 1.92–1.99 (m, 1 H, CH), 2.09–2.12 (t, 2 H, CH₂, *J* = 7.0 Hz), 2.34–2.37 (m, 2 H, CH₂), 2.45–2.48 (m, 2 H, CH₂), 4.02–4.08 (m, 4 H, 2 CH₂), 4.20–4.24 (m, 1 H, CH), 5.83 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH₂), 8.15 (d, 1 H, CONH, *J* = 3.8 Hz), 10.10 (s, 1 H, 3-NH), 10.77 (s, 1H, 7-NH).

(S)-2-(6-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)hexanamido)pentanedioic acid (3a)

To a solution of the diester **8a** (100 mg, 0.22 mmol) was added 1N NaOH (5 mL), and the mixture was stirred under N₂ at room temperature for 1 h. TLC showed the disappearance of the starting material and formation of one major spot at the origin (CHCl₃/MeOH, 5:1). The resulting solution was cooled in an ice bath, and the pH was adjusted to 3–4 with dropwise addition of 1N HCl. The resulting suspension was frozen in a dry ice/acetone bath, thawed in a refrigerator to 4–5 °C, and filtered. The residue was washed with a small amount of cold water and ethyl acetate and dried in vacuo using P₂O₅ to afford 78 mg **3a**: yield 90% as a white powder, mp 145–146 °C decomposed, *R_f* = 0.08 (CHCl₃/MeOH, 5:1). ¹H NMR (DMSO-*d*₆) δ 1.24–1.30 (m, 2 H, CH₂), 1.48–1.58 (m, 4 H, 2 CH₂), 1.71–1.79 (m, 1 H, CH), 1.88–1.95 (m, 1 H, CH), 2.09–2.12 (t, 2 H, CH₂, *J* = 7.5 Hz), 2.24–2.27 (m, 2 H, CH₂, *J* = 7.5 Hz), 2.44–2.47 (m, 2 H, CH₂), 4.16–4.21 (m, 1 H, CH), 5.84 (s, 1 H, CH), 5.95 (s, 2 H, 2-NH₂), 7.99 (d, 1 H, CONH, *J* = 4.0 Hz), 10.10 (s, 1 H, 3-NH), 10.76 (s, 1H, 7-NH), 12.50 (br, 2 H, 2 COOH). Anal. (C₁₇H₂₃N₅O₆ · 2.0 H₂O) C, H, N.

(S)-2-(7-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)heptanamido)pentanedioic acid (3b)

Compound **3b** was synthesized as described for **3a**: yield 91% as a pale yellow powder, mp 116–117 °C decomposed, *R_f* = 0.08 (CHCl₃/MeOH, 5:1). ¹H NMR (DMSO-*d*₆) δ 1.22–1.32 (m, 4 H, 2 CH₂), 1.45–1.58 (m, 4 H, 2 CH₂), 1.71–1.79 (m, 1 H, CH), 1.91–1.98 (m, 1 H,

CH), 2.09–2.12 (t, 2 H, CH₂, *J* = 7.5 Hz), 2.24–2.28 (m, 2 H, CH₂, *J* = 7.5 Hz), 2.44–2.47 (m, 2 H, CH₂), 4.16–4.21 (m, 1 H, CH), 5.84 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH₂), 8.02 (d, 1 H, CONH, *J* = 4.0 Hz), 10.10 (s, 1 H, 3-NH), 10.76 (s, 1H, 7-NH), 12.12 (br, 1 H, 1 COOH), 12.52 (br, 1 H, 1 COOH). Anal. (C₁₈H₂₅N₅O₆ · 0.5 H₂O) C, H, N.

(S)-2-(8-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)octanamido)pentanedioic acid (3c)

Compound **3c** was synthesized as described for **3a**: yield 95% as a yellow powder, mp 135–136 °C decomposed, *R_f* = 0.08 (CHCl₃/MeOH, 5:1). ¹H NMR (DMSO-*d*₆) δ 1.20–1.32 (m, 6 H, 3 CH₂), 1.45–1.58 (m, 4 H, 2 CH₂), 1.71–1.79 (m, 1 H, CH), 1.90–1.98 (m, 1 H, CH), 2.08–2.12 (t, 2 H, CH₂, *J* = 7.5 Hz), 2.24–2.28 (m, 2 H, CH₂, *J* = 7.5 Hz), 2.44–2.47 (t, 2 H, CH₂, *J* = 7.5 Hz), 4.16–4.21 (m, 1 H, CH), 5.84 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH₂), 8.02 (d, 1 H, CONH, *J* = 3.8 Hz), 10.11 (s, 1 H, 3-NH), 10.76 (s, 1H, 7-NH). Anal. (C₁₉H₂₇N₅O₆ · 0.5 H₂O) C, H, N.

(S)-2-(9-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)nonanamido)pentanedioic acid (3d)

Compound **3d** was synthesized as described for **3a**: yield 90% as a pale yellow powder, mp 123–124 °C decomposed, *R_f* = 0.08 (CHCl₃/MeOH, 5:1). ¹H NMR (DMSO-*d*₆) δ 1.20–1.32 (m, 8 H, 4 CH₂), 1.42–1.58 (m, 4 H, 2 CH₂), 1.71–1.79 (m, 1 H, CH), 1.90–1.98 (m, 1 H, CH), 2.08–2.11 (t, 2 H, CH₂, *J* = 7.5 Hz), 2.24–2.28 (m, 2 H, CH₂, *J* = 7.5 Hz), 2.44–2.47 (t, 2 H, CH₂, *J* = 7.5 Hz), 4.16–4.21 (m, 1 H, CH), 5.84 (s, 1 H, CH), 5.94 (s, 2 H, 2-NH₂), 8.01 (d, 1 H, CONH, *J* = 3.8 Hz), 10.11 (s, 1 H, 3-NH), 10.76 (s, 1H, 7-NH). Anal. (C₂₀H₂₉N₅O₆ · 0.5 H₂O) C, H, N.

Molecular modeling and computational studies

The X-ray crystal structure of human GARFTase at 1.98 Å resolution (PDB ID: 1NJS)²² was obtained from the protein database. The human GARFTase crystal structure contains GARFTase complexed with the hydrolyzed form of 10-trifluoroacetyl-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid (10-CF₃CO-DDACTHF). Molecular modeling studies with FRα were carried out using the 2.80 Å crystal structure of human FRα co-crystallized with folic acid (PDB: 4LRH).²³

Docking studies were performed using LeadIT 2.1.3.²⁵ The protonation state of the proteins and the ligands were calculated using the default settings. Water molecules in the active site were permitted to rotate freely. The active site was defined by a sphere of 6.5 Å from the native ligand in the crystal structure. Ligands for docking were built using the molecule builder function in MOE 2010.10²⁶ and energy minimized using the MMF94X forcefield to a constant of 0.05 kcal/mol. Triangle matching was used as the placement method and the docked poses were scored using default settings. The docked poses were exported and visualized in MOE.

In order to validate the docking software for docking the proposed compounds, the native ligand for GARFTase (10-CF₃CO-DDACTHF) and FRα (folic acid) were built using the molecule builder function in MOE, energy minimized and docked using LeadIT 2.1.3 as described above. RMSDs of the docked poses were calculated using an SVL code obtained from the MOE website (www.chemcomp.com) and compared to the conformation of the crystal structure ligands. The best docked pose for 10-CF₃CO-DDACTHF in the human GARFTase crystal structure had an RMSD of 1.0437 Å (Docking score: –40.0853) while the best docked pose for FRα had an RMSD of 0.633 Å (Docking score: –55.5940). Thus, LeadIT 2.1.3 was validated for our docking purposes in GARFTase and FRα.

Reagents for biological studies

[3', 5', 7, 9-³H]Folic acid (25 Ci/mmol) and [¹⁴C(U)]glycine (87mCi/mmol) were purchased from Moravek Biochemicals (Brea, CA). Unlabeled folic acid was purchased from Sigma Chemical Co. (St. Louis, MO). LCV [(6R,S) 5-formyl tetrahydrofolate] was provided by the Drug Development Branch, National Cancer Institute, Bethesda, MD. The sources of the classical antifolate drugs were as follows: MTX, Drug Development Branch, National Cancer Institute (Bethesda, MD); RTX [*N*-(5-[*N*-(3,4-dihydro-2-methyl-4-oxyquinazolin-6-ylmethyl)-*N*-methyl-amino]-2-thienoyl)-*L*-glutamic acid], AstraZeneca Pharmaceuticals (Macclesfield, Cheshire, England); PDX ((2*S*)-2-[[4-[(1*RS*)-1-[(2, 4-diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid), Allos Therapeutics (Henderson, NV); and LMTX (5,10-dideaza-5,6,7,8-tetrahydrofolate) and PMX [*N*-(4-[2-(2-amino-3,4-dihydro-4-oxo-7*H*-pyrrolo[2,3-*d*]pyrimidin-5-yl)ethyl]benzoyl)-*L*-glutamic acid] (Alimta), Eli Lilly and Co. (Indianapolis, IN). Other chemicals were obtained from commercial sources in the highest available purity.

Cell lines and assays of antitumor drug activities

The origin of the engineered CHO cell lines, including the RFC-, PCFT-, and FR α -null MTXR2IIOua^R2-4 (R2), and RFC- (pC43-10), PCFT- (R2/PCFT4), or FR α - (RT16) expressing sublines, were previously described.^{11,12,21} Likewise, pDNA3.1 vector control CHO cells (R2/VC) were reported.^{11,12} The CHO cells were cultured in α -minimal essential medium (MEM) supplemented with 10% bovine calf serum (Invitrogen, Carlsbad, CA), 100 units/ml penicillin/100 μ g/ml streptomycin, and 2 mM *L*-glutamine at 37°C with 5% CO₂. All the R2 transfected cells [PC43-10, RT16, R2/hPCFT4, R2(VC)] were routinely cultured in α -MEM plus 1.5 mg/ml G418. Prior to the cell proliferation assays (see below), RT16 cells were cultured in complete folate-free RPMI 1640 (without added folate) for three days. R2/hPCFT4 and R2(VC) cells were cultured in complete folate-free RPMI 1640 including dFBS (Invitrogen) and 25 nM LCV with 1.5 mg/ml G418. KB human nasopharyngeal carcinoma cells were purchased from the American Type Culture Collection (Manassas, VA). KB cells were routinely cultured in folate-free RPMI 1640 medium, supplemented with 10% fetal bovine serum, penicillin-streptomycin solution, and 2 mM *L*-glutamine at 37°C with 5% CO₂.

For growth inhibition assays, cells (CHO and KB) were plated in 96 well dishes (~2500–5000 cells/well, total volume of 200 μ l medium) with a range of antifolate concentrations.^{11–16} The medium was RPMI 1640 (contains 2.3 μ M folic acid) with 10% dFBS and antibiotics for experiments with R2 and PC43-10 cells. For RT16 and KB cells, cells were cultured in folate-free RPMI media with 10% dFBS and antibiotics supplemented with 2 nM LCV and 2 mM *L*-glutamine. The requirement for FR-mediated drug uptake in these assays was established in parallel incubations including 200 nM folic acid. For R2/hPCFT4 cells, the medium was folate-free RPMI 1640 (pH 7.2) containing 25 nM LCV, supplemented with 10% dFBS, antibiotics, and *L*-glutamine. Cells were routinely incubated for up to 96 h and metabolically active cells (a measure of cell viability) were assayed with CellTiter-blue Cell Viability Assay (Promega, Madison, WI), with fluorescence measured (590 nm emission, 560 nm excitation) using a fluorescence plate reader.^{11–16} Raw data were exported from Softmax Pro software to an Excel spreadsheet for analysis and determinations of IC₅₀s, corresponding to the drug concentrations that result in 50% loss of cell growth.^{11–16}

For some of the *in vitro* growth inhibition studies, the inhibitory effects of the antifolate inhibitors on *de novo* thymidylate biosynthesis (i.e., thymidylate synthase) and *de novo* purine nucleotide biosynthesis (GARFTase and AICARFTase) were tested by co-incubations with thymidine (10 μ M) and adenosine (60 μ M), respectively.^{11–17} For *de novo*

purine nucleotide biosynthesis, additional protection experiments used AICA (320 μ M) to distinguish inhibitory effects at GARFTase from those at AICARFTase.^{11–17}

FR binding assay

Competitive inhibition of [³H]folic acid binding to FR α and FR β using RT16 and D4 CHO cells, respectively, was used to assess relative binding affinities for assorted (anti)folate ligands.^{11,12,14–16} For these experiments, cells ($\sim 1.6 \times 10^6$) were rinsed twice with DPBS, followed by two washes an acidic buffer (10 mM sodium acetate, 150 mM NaCl, pH 3.5) to remove FR-bound folates. Cells were washed twice with ice-cold HEPES-buffered saline (20 mM HEPES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl₂, 5 mM glucose, pH 7.4) (HBS), then incubated in HBS with [³H]folic acid (50 nM, specific activity 0.5 Ci/mmol) in the presence and absence of unlabeled folic acid or antifolates (over a range of concentrations) for 15 min at 0°C. The dishes were rinsed three times with ice-cold HBS, after which the cells were solubilized (0.5 N NaOH) and aliquots measured for radioactivity and protein contents. Protein concentrations were measured with Folin phenol reagent.²⁷ [³H]Folic acid bound to FR α and FR β was calculated as pmol/mg protein and relative binding affinities were calculated in each individual experiment as the inverse molar ratios of unlabeled ligands required to inhibit [³H]folic acid binding by 50%.^{11,12,14–16} By definition, the relative affinity of folic acid is 1. Experiments were performed in triplicate.

In situ GARFT enzyme inhibition assay

Incorporation of [¹⁴C]glycine into [¹⁴C]formyl GAR, as an *in situ* measure of endogenous GARFTase activity, was measured.^{6,11–17} For these experiments, KB cells were seeded in 4 ml complete folate-free RPMI 1640 plus 2 nM LCV in 60 mm dishes at a density of 2×10^6 cells per dish. On the next day, the medium was replaced with 2 ml fresh complete folate-free RPMI 1640 plus 2 nM LCV. Azaserine (4 μ M final concentration) was added in the presence and absence of the antifolate inhibitors. After 30 min, *L*-glutamine (final concentration, 2 mM) and [¹⁴C]glycine (tracer amounts; final specific activity 0.1 mCi/L) were added. Incubations were at 37°C for 15 h, at which time cells were washed (one-time) with ice-cold folate-free RPMI 1640 plus serum. Cell pellets were dissolved in 2 ml 5% trichloroacetic acid at 0°C. The trichloroacetic acid insoluble fraction was removed by centrifugation, solubilized in 0.5N NaOH, and the cell protein contents were measured with Folin phenol reagent.²⁷ The supernatants were extracted twice with 2 ml of ice-cold ether. The aqueous layer was passed through a 1 cm column of AG1x8 (chloride form), 100–200 mesh (Bio-Rad), washed with 10 ml of 0.5N formic acid and then 10 ml of 4N formic acid, and finally eluted with 8 ml 1N HCl. The eluates were collected and determined for radioactivity. The accumulation of [¹⁴C]formyl GAR was calculated as pmol per mg protein over a range of inhibitor concentrations. IC₅₀s were calculated as the concentrations of inhibitors that resulted in a 50% decrease in [¹⁴C]formyl GAR synthesis. Experiments were performed in triplicate.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported in part by grants from the National Institutes of Health, National Cancer Institute CA152316 (LHM and AG), CA166711 (AG and LHM), and CA53535 (LHM), and the Duquesne University Adrian Van Kaam Chair in Scholarly Excellence (AG). Ms. Mitchell-Ryan was supported by T32 CA009531 (LHM) and F31 CA165853 (SM-R).

ABBREVIATIONS USED

AICA	5-aminoimidazole-4-carboxamide
AICARFTase	5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase
CHO	Chinese hamster ovary
dFBS	dialyzed fetal bovine serum
DPBS	Dulbecco's phosphate-buffered saline
FR	folate receptor
FPGS	folylpolyglutamate synthetase
GAR	glycinamide ribonucleotide
GARFTase	glycinamide ribonucleotide formyltransferase
HBSS	Hank's balanced salts solution
HBS	HEPES-buffered saline
LCV	leucovorin
LMTX	Lometrexol
MTX	methotrexate
MEM	minimal essential media
PMX	Pemetrexed
PDX	Pralatrexate
PCFT	proton-coupled folate transporter
RTX	Raltitrexed
RFC	reduced folate carrier
SAR	structure-activity relationship
10-CF₃CO-DDACTHF	10-trifluoroacetyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid

References

1. Matherly LH, Hou Z, Deng Y. Human Reduced Folate Carrier: Translation of Basic Biology to Cancer Etiology and Therapy. *Cancer Metastasis Rev.* 2007; 26:111–128. [PubMed: 17334909]
2. Elnakat H, Ratnam M. Distribution, Functionality and Gene Regulation of Folate Receptor Isoforms: Implications in Targeted Therapy. *Adv Drug Deliv Rev.* 2004; 56:1067–1084. [PubMed: 15094207]
3. Yang J, Vlashi E, Low P. Folate-linked Drugs for the Treatment of Cancer and Inflammatory Diseases. *Subcell Biochem.* 2012; 56:163–179. [PubMed: 22116699]
4. Zhao R, Matherly LH, Goldman ID. Membrane Transporters and Folate Homeostasis: Intestinal Absorption and Transport into Systemic Compartments and Tissues. *Expert Rev Mol Med.* 2009; 11:e4. [PubMed: 19173758]
5. Kugel Desmoulin S, Hou Z, Matherly LH, Gangjee A. The Human Proton-coupled Folate Transporter: Biology and Therapeutic Applications to Cancer. *Cancer Biol Ther.* 2012; 13(14):1–19. [PubMed: 22198566]
6. Kugel Desmoulin S, Wang L, Hales E, Polin L, White K, Kushner J, Stout M, Hou Z, Cherian C, Gangjee A, Matherly LH. Therapeutic Targeting of a Novel 6-Substituted Pyrrolo[2,3-d]pyrimidine

- Thienoyl Antifolate to Human Solid Tumors Based on Selective Uptake by the Proton-Coupled Folate Transporter. *Mol Pharmacol.* 2011; 80:1096–1107. [PubMed: 21940787]
7. Visentin M, Zhao R, Goldman ID. The Antifolates. *Hematol Oncol Clin North Am.* 2012; 26:629–648. [PubMed: 22520983]
 8. Gonen N, Assaraf YG. Antifolates in Cancer Therapy: Structure, Activity and Mechanisms of Drug Resistance. *Drug Resistance Updates.* 2012; 15:183–210. [PubMed: 22921318]
 9. Sirotnak FM, DeGraw JI, Colwell WT, Piper JR. A New Analogue of 10-Deazaaminopterin with Markedly Enhanced Curative Effects Against Human Tumor Xenografts in Mice. *Cancer Chemother Pharmacol.* 1998; 42:313–318. [PubMed: 9744777]
 10. Zhao R, Goldman ID. Resistance To Antifolates. *Oncogene.* 2003; 22:7431–7457. [PubMed: 14576850]
 11. Deng Y, Wang Y, Cherian C, Hou Z, Buck SA, Matherly LH, Gangjee A. Synthesis and Discovery of High Affinity Folate Receptor-Specific Glycinamide Ribonucleotide Formyltransferase Inhibitors with Antitumor Activity. *J Med Chem.* 2008; 51:5052–5063. [PubMed: 18680275]
 12. Deng Y, Zhou X, Desmoulin SK, Matherly LH, Gangjee A. Synthesis and Biological Activity of a Novel Series of 6-Substituted Thieno[2,3-*d*]pyrimidine Antifolate Inhibitors of Purine Biosynthesis with Selectivity for High Affinity Folate Receptors over the Reduced Folate Carrier and Proton-Coupled Folate Transporter for Cellular Entry. *J Med Chem.* 2009; 52:2940–2951. [PubMed: 19371039]
 13. Desmoulin SK, Wang Y, Matherly LH, Gangjee A. Targeting the Proton-Coupled Folate Transporter for Selective Delivery of 6-Substituted [2,3-*d*] pyrimidine Antifolate Inhibitors of *de novo* Purine Biosynthesis in the Chemotherapy of Solid Tumors. *Molecular Pharmacology.* 2010; 78:577–587. [PubMed: 20601456]
 14. Wang L, Cherian C, Desmoulin SK, Polin L, Deng Y, Wu J, Hou Z, White K, Kushner J, Matherly LH, Gangjee A. Synthesis and Antitumor Activity of a Novel Series of 6-Substituted Pyrrolo[2,3-*d*]pyrimidine Thienoyl Antifolate Inhibitors of Purine Biosynthesis with Selectivity for High Affinity Folate Receptors and the Proton-Coupled Folate Transporter over the Reduced Folate Carrier for Cellular Entry. *J Med Chem.* 2010; 53:1301–1318.
 15. Wang L, Desmoulin SK, Matherly LH, Gangjee A. Synthesis, Biological, and Antitumor Activity of a Highly Potent 6-Substituted Pyrrolo[2,3-*d*] pyrimidine Thienoyl Antifolate Inhibitor with Proton-coupled Folate Transporter and Folate Receptor Selectivity over the Reduced Folate Carrier that Inhibits β -Glycinamide Ribonucleotide Formyltransferase. *J Med Chem.* 2011; 54:7150–7164. [PubMed: 21879757]
 16. Wang L, Cherian C, Desmoulin SK, Matherly LH, Gangjee A. Synthesis and Biological Activity of 6-Substituted Pyrrolo[2,3-*d*]pyrimidine Thienoyl Regioisomers as Inhibitors of *de novo* Purine Biosynthesis with Selectivity for Cellular Uptake by High Affinity Folate Receptors and the Proton-Coupled Folate Transporter over the Reduced Folate Carrier. *J Med Chem.* 2012; 55:1758–1770. [PubMed: 22243528]
 17. Beardsley GP, Moroson BA, Taylor EC, Moran RG. A New Antimetabolite, 5,10-Dideaza-5,6,7,8-Tetrahydrofolate is a Potent Inhibitor of *De Novo* Purine Synthesis. *J Biol Chem.* 1989; 264:328–333. [PubMed: 2909524]
 18. Ray MS, Muggia FM, Leichman CG, Grunberg SM, Nelson RL, Dyke RW, Moran RG. Phase I Study of (6R)-5,10-Dideazatetrahydrofolate: A Folate Antimetabolite Inhibitory to *De Novo* Purine Synthesis. *J Natl Cancer Inst.* 1993; 85:1154–1159. [PubMed: 8320744]
 19. Baldwin SW, Tse A, Gossett LS, Taylor EC, Rosowsky A, Shih C, Moran RG. Structural Features of 5,10-Dideaza-5,6,7,8-Tetrahydrofolate That Determine Inhibition of Mammalian Glycinamide Ribonucleotide Formyltransferase. *Biochemistry.* 1991; 30:1997–2006. [PubMed: 1993209]
 20. Habeck LL, Mendelsohn LG, Shih C, Taylor EC, Colman PD, Gossett LS, Leitner TA, Schultz RM, Andis SL, Moran RG. Substrate Specificity of Mammalian Folylpoylglutamate Synthetase for 5,10-Dideazatetrahydrofolate Analogs. *Mol Pharmacol.* 1995; 48:326–333. [PubMed: 7651366]
 21. Wong SC, Proefke SA, Bhushan A, Matherly LH. Isolation of Human cDNAs That Restore Methotrexate Sensitivity and Reduced Folate Carrier Activity in Methotrexate Transport-Defective Chinese Hamster Ovary Cells. *J Biol Chem.* 1995; 270:17468–17475. [PubMed: 7615551]

22. Zhang Y, Desharnais J, Marsilje TH, Li C, Hedrick MP, Gooljarsingh LT, Tavassoli A, Benkovic SJ, Olson AJ, Boger DL, Wilson IA. Rational Design, Synthesis, Evaluation, and Crystal Structure of a Potent Inhibitor of Human GAR Tfase: 10-(Trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic Acid. *Biochemistry*. 2003; 42:6043–6056. [PubMed: 12755606]
23. Chen C, Ke J, Zhou XE, Brunzelle JS, Li J, Yong E-L, Xu HE, Melcher K. Structural Basis For Molecular Recognition of Folic Acid by Folate Receptors. *Nature*. 2013; 500:486–489. [PubMed: 23851396]
24. Wibowo AS, Singh M, Reeder KM, Carter JJ, Kovach AR, Meng W, Ratnam M, Zhang F, Dann CE 3rd. Structures of Human Folate Receptors Reveal Biological Trafficking States and Diversity in Folate and Antifolate Recognition. *Proc Natl Acad Sci U S A*. 2013 Aug 9. Epub ahead of print.
25. LeadIT 2.1.3; BioSolveIT GmbH Sankt. Augustin; Germany: 2011.
26. MOE. Chemical Computing Group; Montreal, Quebec, Canada: 2010. p. 10
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein Measurement With the Folin Phenol Reagent. *J Biol Chem*. 1951; 193:265–275. [PubMed: 14907713]

Figure 1.
Structures of clinically relevant antifolates transported by RFC.

Figure 2.

6-Substituted non-benzoyl straight chain compounds 3a–d, based on lometrexol (LMTX) and compounds 1a–c, showing replacement of the phenyl ring in compounds 2a–2b by 2–5 methylene groups.

Figure 3. Binding of non-benzoyl 5- and 6-substituted pyrrolo[2,3-*d*]pyrimidine analogs (3a–d and 7e–h) to FR α (RT16) and FR β (D4), compared to compounds 2a and 2b

Data are shown for the effects of the unlabeled ligands with FR α -expressing RT16 and FR β -expressing D4 CHO cells. Binding affinities for assorted folate/antifolate substrates were determined over a range of ligand concentrations and were calculated as the inverse molar ratios of unlabeled ligands required to inhibit [^3H]folic acid binding by 50%. Relative binding affinities for individual experiments were normalized to that for unlabeled folic acid which was assigned a value of 1.0. For the various ligands, results are presented as mean values $\pm$ standard errors from 3 experiments. Details for the binding assays are provided in the Experimental Section. Undefined abbreviations: FA, folic acid. The results for compounds **2a** and **2b** were previously published.¹¹

Figure 4. Protection of KB cells from growth inhibition by non-benzoyl 6-substituted pyrrolo[2,3-*d*]pyrimidine analogs **3b–d, in the presence of nucleosides and 5-aminoimidazole-4-carboxamide (AICA)**

Proliferation inhibition was measured for KB cells over a range of concentrations of compounds **3b–d**, as shown, in complete folate-free RPMI1640 with 2 nM LCV in the absence of other additions (labeled “No additions”), or in the presence of 200 nM folic acid (labeled “Folate Added”), adenosine (60 μ M), thymidine (10 μ M), adenosine plus thymidine, or AICA (320 μ M). Cell densities were measured with CellTiter BlueTM fluorescence dye and a fluorescence plate reader. Results were normalized to cell densities in the absence of drug. Results shown are representative data of experiments performed in triplicate.

Figure 5. *In situ* GARFTase inhibition assay

For the *in situ* assays, incorporation of [^{14}C]glycine into [^{14}C]formyl GAR was measured in KB tumor cells cultured for 15 h in complete folate-free RPMI 1640 plus 2 nM LCV. Details are described in the Experimental Section. Results are presented as a percent of control treated without drugs for KB cells treated with nanomolar concentrations of **3b–d**. Results are presented as mean IC_{50} values $\pm$ standard errors. Mean IC_{50} s ($\pm$ SEs) were calculated as 2.89 ($\pm$ 0.62) nM for **3b**, 5.49 ($\pm$ 1.36) nM for **3c**, and 9.62 ($\pm$ 0.98) nM for **3d**. For comparison, IC_{50} s for compounds **2a** and **2b** were 18 ($\pm$ 2) nM and 6.8 ($\pm$ 0.9) nM, respectively.¹¹

Figure 6. Stereoview. Overlay of the docked pose of 3c (white) with 10-CF₃CO-DDACTHF (purple) in human GARFTase (PDB ID: 1NJS).²²

Figure 7.
Stereoview. Overlay of the docked pose of compound 3c (white) with folic acid (blue) in human FR α (PDB ID: 4LRH).²³

CHEMISTRY

Scheme 1.

Table 1

IC₅₀s (in nM) for 6-substituted pyrrolo[2,3-*d*]pyrimidine antifolates and classical antifolates in RFC-, PCFT-, and FR-expressing cell lines

Growth inhibition assays were performed for CHO sublines engineered to express human RFC (PC43-10), FRs α and β (RT16 and D4, respectively), or PCFT (R2/PCFT4), for comparison with transporter-null [R2, R2(VC)] CHO cells, and for the KB human tumor subline (expresses RFC, FR α , and PCFT), as described in the Experimental Section. For the FR experiments, growth inhibition assays were performed in the presence and the absence of 200 nM folic acid (FA). The data shown are mean values from 3–10 experiments (plus/minus SEM in parentheses). Results are presented as IC₅₀ values, corresponding to the concentrations that inhibit growth by 50% relative to cells incubated without drug. Data for MTX, PMX, RTX, and LMTX, and for compounds **2a–d** were previously published.^{11,13} The structures for the classical antifolate drugs are shown in Figure 1 and those for compounds **7e–h** and **3a–d** are shown in Figure 2 and Scheme 1.

Antifolate	hRFC		hFR α		hFR β		hPCFT		hRFC/FR α /hPCFT	
	PC43-10	R2	RT16	RT16 (+FA)	D4	D4 (+FA)	R2/hPCFT4	R2(VC)	KB	KB (+FA)
2a	648.6(38.1)	>1000	4.1(1.6)	>1000	5.6(1.2)	>1000	23.0(3.3)	>1000	1.7(0.4)	>1000
2b	>1000	>1000	6.3(1.6)	>1000	10(2)	>1000	213(28)	>1000	1.9(0.7)	>1000
2c	>1000	>1000	54(21)	>1000	80(9)	>1000	>1000	>1000	13(7.2)	>1000
2d	>1000	>1000	162(18)	>1000	198(34)	>1000	>1000	>1000	23(12)	>1000
7e	>1000	>1000	>1000	>1000	>1000	>1000	>1000	>1000	>1000	>1000
7f	>1000	>1000	>1000	>1000	>1000	>1000	>1000	>1000	>1000	>1000
7g	>1000	>1000	>1000	>1000	>1000	>1000	>1000	>1000	>1000	>1000
7h	>1000	>1000	>10000	>1000	>1000	>1000	>1000	>1000	>1000	>1000
3a	>1000	>1000	>1000	>1000	214(62)	>1000	>1000	>1000	200.3(34.6)	>10000
3b	>1000	>1000	47.1(16.5)	>1000	10.55(3.69)	>1000	>1000	>1000	7.9(0.72)	>1000
3c	>1000	>1000	8.54(1.53)	>1000	0.87(0.12)	>1000	>1000	>1000	1.10(0.88)	>1000
3d	>1000	>1000	12.31(3.14)	>10000	3.99(0.57)	>1000	>1000	>1000	1.48(0.04)	>1000
LMTX	12(2.3)	>1000	12(8)	188(41)	2.6(1.0)	275(101)	38.0(5.3)	>1000	1.2(0.6)	31(7)
MTX	12(1.1)	216(8.7)	114(31)	461(62)	106(11)	211(43)	121(17)	>1000	6.0(0.6)	20(2.4)
PDX	0.69(0.07)	819(94)	168(50)	>1000	ND	ND	57(12)	>1000	0.47(0.20)	1.94(0.28)
PMX	138(13)	894(93)	42(9)	388(68)	60(8)	254(78)	13.2(2.4)	974.0(18.1)	68(12)	327(103)
RTX	6.3(1.3)	>1000	15(5)	>1000	22(10)	746(138)	99.5(11.4)	>1000	5.9(2.2)	22(5)

ND: not determined.